Evidence map›Paper›PMID 40163352›Full record

ArticleCancer research2025

The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.

Nancy Klemm, Roman R Schimmer, Nils K Konrad, Flavian Thelen, Jonas Fullin, Ebru Topçu, Christian Koch, Milena Treacy, Matthew Joseph Leventhal, Marco M Bühler and 12 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Antigen-directed p53 restoration inFrontiers in oncology · 2026
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Nancy KlemmDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0009-0000-6694-0132
Roman R SchimmerDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0846-8508
Nils K KonradDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0009-0005-5846-7548
Flavian ThelenDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-9372-1995
Jonas FullinDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0009-0009-8109-3790
Ebru TopçuDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-1459-4893
Christian KochDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0009-0000-0681-4265
Milena TreacyDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0009-0007-2976-0889
Matthew Joseph LeventhalDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5995-5202
Marco M BühlerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0850-3326
Veronika LysenkoDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-6886-5444
Alexandre P A TheocharidesDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-1535-8692
Kari J KurppaInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0001-8286-2429
Stefan BalabanovDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-2292-9297
Tuncay BaubecDepartment of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8474-6587
Andrei V KrivtsovDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5511-1686
Peter G MillerCenter for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-6797-9335
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9099-4728
Benjamin L EbertDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0197-5451
Markus G ManzDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-4676-7931
Cesar Nombela-ArrietaDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0415-259X
Steffen BoettcherDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0001-9937-0957

Funding

European Hematology Association (EHA) KOG-202209-02593Helmut Horten Stiftung (Helmut Horten Foundation)Jacques und Gloria Gossweiler-Stiftung (JGGF)KRAK-Physician Scientist FellowshipKrebsliga Schweiz (Swiss Cancer League) KFS-4885-08-2019National Institutes of Health (NIH) K08-CA263181Promedica StiftungSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030_184747/1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030_197562/1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030_219699
6 · The paper itself

Abstract

Missense mutants of p53, such as the frequent hotspot variant R248Q, exert a dominant-negative effect (DNE) on wild-type (WT) p53 in cancer cells with monoallelic TP53 mutations. However, the precise functional and molecular mechanisms of the DNE have remained elusive due to a lack of appropriate model systems. In this study, we developed a variety of model systems, including CRISPR-edited human isogenic cell lines and transcriptional reporter cell lines, and targeted protein degradation assays that were combined with functional and molecular analyses to functionally characterize the DNE. Formation of heterotetramers between R248Q and WT p53 impaired proper WT p53 functionality by preventing DNA binding and subsequent target gene transactivation. Furthermore, the markedly increased protein half-life of R248Q led to supraphysiologic levels of R248Q, which was critically required for the DNE. Drug-induced targeted protein degradation of R248Q to lower the R248Q:WT ratio restored the transcriptional activity of WT p53, induced antiproliferative effects in cancer cells in vitro, and elicited strong therapeutic activity in vivo. Together, this study provides mechanistic insights into the DNE of p53 missense mutants and indicates that the DNE represents a promising therapeutic target. Significance: Heterotetramerization between R248Q mutant and wild-type p53 in conjunction with supraphysiologic p53R248Q accumulation underlies the dominant-negative effect, highlighting the need to develop pharmacologic strategies to decrease the elevated R248Q:WT ratio. See related commentary by Gencel-Augusto and Lozano, p. 1955.

Indexed as

Mutation, MissenseNeoplasmsTumor Suppressor Protein p53AnimalsCell Line, TumorCell ProliferationFemaleHalf-LifeHumansMiceProteolysisTranscriptional ActivationXenograft Model Antitumor AssaysTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40163352
PMCPMC12127799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.